Multiple myeloma is a type of cancer that affects certain white blood cells, called plasma cells, in the bone marrow. The condition can cause people to feel unwell and extremely tired. It can also affect their bones and other organs, such as the kidneys.
The American Cancer Society estimates that in the United States, doctors will diagnose multiple myeloma in 19,320 men and 15,600 women in 2021. Researchers are continually working on new treatments to extend life expectancy for people with this condition.
Multiple myeloma treatment has come a long way since the days when chemotherapy was the only option. Today, more therapies exist than ever before.
Doctors can now customize a treatment plan for each person based on their diagnosis and unique needs. Options may include chemotherapy with stem cell transplantation, immunotherapy drugs, targeted therapies, and novel drug combinations.
This article looks at multiple myeloma treatment options, including chemotherapy and other drugs, bone marrow transplants, and radiation therapy. It also looks at a persons possible outlook following a multiple myeloma diagnosis.
Multiple myeloma is a type of cancer that changes someones plasma cells. These specialized cells are typically located in the bone marrow, and they play an essential role in the immune system.
If a person has multiple myeloma, the altered, cancerous plasma cells build up in the bone marrow, which means that there is not enough space for healthy blood cells. Instead of making antibodies that protect an individual from invading germs, the cancerous cells make an abnormal protein called monoclonal immunoglobulin, or monoclonal protein (M-protein).
Doctors may find these elevated M-proteins while testing the blood for another condition. They may also make a diagnosis because they suspect that someone has multiple myeloma based on their symptoms.
Although there are no specific causes of multiple myeloma, it appears to be more common among males, Black people, and individuals aged 45 years and above.
When treating multiple myeloma, doctors typically use chemotherapy to prepare the body for a stem cell transplant.
Chemotherapy is a powerful form of treatment that kills cells that divide and multiply quickly, such as cancer cells. However, healthy cells that grow rapidly may also become chemotherapy targets. This includes cells in the bone marrow, digestive tract, reproductive system, and hair follicles.
When chemotherapy damages healthy cells, it can cause side effects, including:
People undergoing chemotherapy may also develop low blood counts as a side effect of treatment. Having a low blood count means that an individual has an increased risk of infection. They bruise and bleed more easily, feel fatigued, and could be short of breath.
Most chemotherapy side effects disappear once a person has completed treatment.
Monoclonal antibodies are a form of immunotherapy that uses someones immune system to fight the cancer cells by targeting specific proteins. Some monoclonal antibodies target the CD38 protein, while others target the SLAM57 protein. Myeloma cells have both proteins.
Monoclonal antibodies affect cancer cells directly and help the immune system attack them. Doctors often use this treatment in combination with other types of drugs.
These drugs can cause a reaction at the time of administration or a few hours after. Some symptoms of a reaction include:
Immunomodulating drugs regulate certain aspects of the immune system. They can prevent some types of growth signals for cancer cells, activate specific immune cells, and kill myeloma cells.
The first immunomodulating drug that researchers developed was called thalidomide, and it caused severe congenital disabilities. Researchers still question the safety of newer immunomodulating drugs related to thalidomide, and people can only receive them through special programs.
The side effects of immunomodulating drugs depend on the specific drug but can include:
Steroids are an essential treatment for all stages of multiple myeloma. At high doses, steroids can kill cancer cells. They can also stop white blood cells from going to the disease-affected areas, thereby decreasing inflammation and relieving pain and pressure.
Some side effects of steroids include:
Long-term steroid use may suppress the immune system and weaken the bones. However, these side effects often go away once the steroid treatment is over.
People with myeloma can develop weak bones that may break easily. Bone modifying drugs called bisphosphonates can help strengthen the bones and slow down the weakening process. They can also reduce pain levels.
One rare but severe side effect of bone modifying drugs is osteonecrosis of the jaw. The drugs can destroy the jawbone and create an open wound that cannot heal. The open sore can lead to infection, and some people also experience tooth loss in the area.
One way to prevent this is by maintaining good oral hygiene and treating tooth or gum infections right away.
The standard of care for those with multiple myeloma involves a combination of high-dose chemotherapy and a bone marrow transplant. Getting a bone marrow transplant often means that an individual remains disease-free for a long time.
Whether or not someone is a good candidate for a bone marrow transplant depends on many factors, such as their age and the stage of their myeloma.
People frequently receive chemotherapy before a bone marrow transplant, which weakens their immune system and can lead to infections.
Some other side effects of bone marrow transplants can include:
Radiation therapy uses rays of particles to damage multiple myeloma cells and prevent them from growing. Not only can radiation therapy treat multiple myeloma, but it can also reduce complications from bone disease.
Like chemotherapy, radiation therapy can damage some normal cells, especially those that divide quickly. However, most healthy cells recover fully from the effects of radiation therapy.
Some side effects of radiation therapy include fatigue and a loss of appetite. A person may also have some sensitivity and irritation in the skin around the treatment area.
Doctors cannot cure multiple myeloma. There are times when it may lie dormant, but the cancer usually returns. For some people, multiple myeloma may present with no symptoms and progress slowly. A good response to initial treatment can lead to a promising outlook.
Even when treatment is over, regular follow-up testing is necessary to monitor for relapse. The 5-year survival rate for multiple myeloma in 20102016 was 53.9%. This rate has been steadily increasing.
Multiple myeloma is a cancer that affects the plasma cells in the bone marrow. There are many treatment options for multiple myeloma.
The standard of care is a combination of chemotherapy and radiation therapy. In most cases, treatment includes a combination of multiple therapies and drugs.
Multiple myeloma has no cure, but people can go into remission. People in remission must have regular follow-up testing to monitor for disease recurrence.
Read the rest here:
- Issue: Cell Stem Cell - August 2nd, 2021
- Stem Cell Therapy & Alternative Medicine in Mexico ... - August 2nd, 2021
- Fetal Stem Cell - an overview | ScienceDirect Topics - August 2nd, 2021
- Stem cell therapy - SlideShare - August 2nd, 2021
- Essent Biologics Launches Human Mesenchymal Stem Cells For ... - August 2nd, 2021
- From Cells to Organs: The Present and Future of Regenerative Medicine - DocWire News - August 2nd, 2021
- USC Stem Cell scientists explore the latent regenerative potential of the inner ear - USC News - August 2nd, 2021
- Refining epilepsy treatment with brain organoids and AI - Monash University - August 2nd, 2021
- Astellas and Minovia link up on mitochondrial cell therapy programs - The Pharma Letter - August 2nd, 2021
- Stem Cell Scientists Explore the Latent Regenerative Potential of the Inner Ear - SciTechDaily - July 31st, 2021
- Colin Jackson health: Im in constant pain Athlete to undergo stem cell therapy to help - Express - July 31st, 2021
- The Talking Man: New Advances In Regenerative Medicine - Forbes - July 31st, 2021
- Medipost's clinical trial approved to evaluate efficacy of knee osteoarthritis treatment - Aju Business Daily - July 31st, 2021
- A Phase II Study of Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide Before Stem Cell Transplantation in People with... - July 31st, 2021
- Background should not be a barrier to access stem cell transplant treatment and care - PoliticsHome - July 31st, 2021
- Treatment Approaches for Patients With R/R DLBCL - Targeted Oncology - July 31st, 2021
- Global $57.4 Billion Cell And Gene Therapy Manufacturing Market to 2028 - Rising Pressure on Drug Developers/Manufacturers to Meet the Growing Market... - July 31st, 2021
- Acute Myeloid Leukemia Fungal Infections: Types and Treatment - Healthline - July 31st, 2021
- Overview of DLBCL - Targeted Oncology - July 31st, 2021
- Roundtable Discussion: Participants Evaluate the Use of Transplant and MRD in Newly Diagnosed Multiple Myeloma - Targeted Oncology - July 31st, 2021
- Hematopoietic Stem Cell Transplantation (HSCT) Market: Allogeneic transplant is projected to continue to hold a dominant market share - BioSpace - July 27th, 2021
- Researchers develop a cell culture test to detect substances that harm the placenta and embryo - News-Medical.net - July 27th, 2021
- FDA Approves KEYTRUDA (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With... - July 27th, 2021
- Cryopreservation of Unrelated Donor SCTs Safe, Effective in Patients Who Underwent HSCT - Hematology Advisor - July 27th, 2021
- Combination drug therapy can significantly benefit patients with newly diagnosed blood cancer - The Institute of Cancer Research, London - The... - July 25th, 2021
- Study proposes repurposed drug to treat COVID-19 - The Hindu - July 25th, 2021
- Injecting mice with pulmonary endothelial cells can reverse symptoms of emphysema - News-Medical.Net - July 25th, 2021
- FDA gives speedy review to Bayer's Parkinson's stem cell therapy - - pharmaphorum - July 23rd, 2021
- Stemming the tide of stem-cell treatment scams - Houston Chronicle - July 23rd, 2021
- Regenerative Medicine provides new hope and healing - Summit Daily News - July 23rd, 2021
- Emphysema Reversed in Mice Given Injection of Healthy Pulmonary Endothelial Cells - Genetic Engineering & Biotechnology News - July 23rd, 2021
- Nelson: Gimpy girls have different means of recovery - Watertown Public Opinion - July 23rd, 2021
- Gene Therapy Protects Optic Nerve Cells and Vision in Mice with Retinal Injury and Glaucoma - Genetic Engineering & Biotechnology News - July 23rd, 2021
- Has COVID-19 Opened up the Route to Market for Cell and Gene Therapy? - Pharmaceutical Executive - July 23rd, 2021
- Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments - OncLive - July 23rd, 2021
- Bluebird, with little fanfare, is first to bring a second gene therapy to market - BioPharma Dive - July 23rd, 2021
- Belumosudil Granted Full Approval for Treatment of Chronic GVHD by FDA - Cancer Network - July 21st, 2021
- Creative Medical Technology Holdings Announces MyeloCelz The Company's Second Regenerative Immunotherapy Product - PRNewswire - July 21st, 2021
- Stem Cell Therapy Gets Fast Track Status for Parkinson Disease - Monthly Prescribing Reference - July 21st, 2021
- Stem cell model reveals how COVID-19 can infect the brain - Study Finds - July 21st, 2021
- Donating a chance at life: Kokomo teacher donates stem cells to 75-year-old woman through Be the Match - Kokomo Perspective - July 21st, 2021
- Young Patients With Multiple Myeloma May Benefit From Tandem Autologous Hematopoietic Stem Cell Transplantation - Hematology Advisor - July 21st, 2021
- Emerging Quadruplets, Novel Targets, and Immunotherapy Advances Personalized Medicine in Multiple Myeloma - OncLive - July 21st, 2021
- BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease - Yahoo Finance - July 21st, 2021
- YOUR HEALTH: Finding cures by tracking cells - WQAD.com - July 21st, 2021
- Study shows promise of combining radiation therapy with dendritic-cell vaccines for breast cancer - News-Medical.Net - July 21st, 2021
- Profilin 1 Protein and Its Implications for Cancers - Cancer Network - July 17th, 2021
- Developmental Interest in Allogeneic PlacentaDerived Cell Therapies Expands - OncLive - July 17th, 2021
- For Patients with HIV and Cancer, a Multidisciplinary Treatment Approach is Critical - Targeted Oncology - July 17th, 2021
- Times really up! FDA authority to crack down on regenerative medicines upheld as grace period ends - JD Supra - July 15th, 2021
- The Memphis Institute of Regenerative Medicine Rebrands To Reflect Statewide Reach - UTHSC News - July 15th, 2021
- Dr. Sperling on Future Research With CAR T-Cell Therapy in Multiple Myeloma - OncLive - July 15th, 2021
- TiTAN-1 Trial of GEN-011 Initiates Treatment in Patients With Solid Tumors - Targeted Oncology - July 15th, 2021
- Saving a life, fixing the world - The Jewish Standard - July 15th, 2021
- Exosome spray may be better able to heal damaged hearts - New Atlas - July 15th, 2021
- Prime Medicine uncloaks with $315M to push 'search and replace' gene editing treatments - FierceBiotech - July 13th, 2021
- Dr. Sallman on Unmet Treatment Needs in Higher-Risk MDS - OncLive - July 13th, 2021
- U.S. Stem Cell, Inc The New Generation Company In The ... - July 11th, 2021
- Stem Cell Therapy - Stemedix | Regenerative Medicine Also ... - July 11th, 2021
- FIRM, CAS further cooperate to advance reproductive medicine research_china.org.cn - China.org.cn - July 11th, 2021
- England's drug price watchdog rejects Orchard's groundbreaking gene therapy after first round of talks - FiercePharma - July 11th, 2021
- ARO-HIF2 Shows Signals of Activity, Safety in Clear Cell Renal Cell Carcinoma - Targeted Oncology - July 9th, 2021
- Gene therapy for sickle cell disease: progress and competition - BioPharma Dive - July 9th, 2021
- Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere... - July 9th, 2021
- Dr. Sperling on Future Research Directions With Ide-Cel in Multiple Myeloma - OncLive - July 9th, 2021
- More than $25m awarded to Monash researchers for vital medical research - Monash University - July 9th, 2021
- Magnetically-guided delivery of therapeutic stem cells into the brain - Advanced Science News - July 7th, 2021
- Beyond CAR-T: New Frontiers in Living Cell Therapies - UCSF News Services - July 7th, 2021
- Stem cell therapy could make significant impact as opioid alternative - The Pharma Letter - July 7th, 2021
- Institute for Stem Cell Biology and Regenerative Medicine ... - July 5th, 2021
- Home - World Stem Cell Summit - July 5th, 2021
- Stem Cell Therapy & Regenerative Medicine Clearwater, FL ... - July 5th, 2021
- Ethical Issues in Stem Cell Research - July 5th, 2021
- Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com - Business Wire - July 3rd, 2021
- Regenerative Therapy Makes Headway in HF ... in the Right Patients - MedPage Today - July 3rd, 2021
- A New Era For FDA Regulation Of Cell And Tissue Products - Law360 - July 3rd, 2021
- Anti-CD22 CAR-T cell therapy as a salvage treatment - OTT | OTT - Dove Medical Press - July 3rd, 2021
- Studies Offer Promising Data on CAR T-cell Therapy in B-ALL, Multiple Myeloma - AJMC.com Managed Markets Network - July 3rd, 2021
- The cell therapy manufacturing market is projected to reach USD 14.5 billion by 2030, growing at - GlobeNewswire - July 3rd, 2021
- Cellular Model of a Developing Mouse Is Built With Spatial Resolution - Technology Networks - July 3rd, 2021